| Not Yet Recruiting | A Randomized Study of a Short Duration Therapy for Candidemia NCT06859671 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Not Yet Recruiting | A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncom NCT06907992 | Augusta University | — |
| Completed | Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal NCT07272915 | Central Hospital, Nancy, France | — |
| Recruiting | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia an NCT05421858 | Basilea Pharmaceutica | Phase 3 |
| Terminated | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin NCT05178862 | Scynexis, Inc. | Phase 3 |
| Active Not Recruiting | Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia NCT04979052 | Radboud University Medical Center | Phase 2 |
| Completed | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in A NCT04368559 | Mundipharma Research Limited | Phase 3 |
| Completed | An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida NCT04148287 | Basilea Pharmaceutica | Phase 2 |
| Unknown | Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood NCT04147975 | HelixBind, Inc. | — |
| Completed | Echinocandins Versus Azoles for Candidemia Treatment NCT03799172 | Hospices Civils de Lyon | — |
| Completed | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis NCT03667690 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia NCT03604705 | Basilea Pharmaceutica | Phase 2 |
| Completed | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidia NCT03363841 | Scynexis, Inc. | Phase 3 |
| Completed | CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidias NCT02734862 | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Withdrawn | Bio-assay Development and Implementation for Fungal Infection Detection NCT02333266 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Non-Conventional Microbiological Methods in the Diagnosis of Candidemia NCT07422155 | Institute of Oncology Ljubljana | N/A |
| Completed | Serial Therapeutic and Antifungal Monitoring Protocol NCT02163889 | T2 Biosystems | — |
| Completed | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candid NCT02244606 | Scynexis, Inc. | Phase 2 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia NCT01982071 | Astellas Pharma China, Inc. | Phase 4 |
| Completed | Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study) NCT01752166 | T2 Biosystems | — |
| Completed | Genetic Susceptibility Factors for Candidemia. NCT02841501 | University Hospital, Lille | — |
| Completed | Negative Beta Glucan in ICU Patients NCT01734525 | Universidade Federal do Rio de Janeiro | Phase 4 |
| Completed | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV NCT00802854 | Pfizer | — |
| Completed | Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT) NCT01525095 | T2 Biosystems | — |
| Unknown | Risk Factor and Outcome of Candidemia NCT01249313 | China Medical University Hospital | — |
| Unknown | Anidulafungin Pharmacokinetics in Intensive Care Unit Patients NCT01438216 | Amsterdam UMC, location VUmc | — |
| Completed | Early- and Late-onset Candidemia NCT01406093 | Giovanni Di Perri | — |
| Completed | SIHAM Candidemia Network:An Observational Study NCT01281345 | Society of Indian Human & Animal Mycologist | — |
| Unknown | Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia NCT01270490 | Radboud University Medical Center | Phase 3 |
| Terminated | A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidem NCT01176058 | Pfizer | Phase 3 |
| Completed | A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093) NCT01174147 | Merck Sharp & Dohme LLC | — |
| Withdrawn | UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients NCT01622595 | University of Arkansas | — |
| Unknown | Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Ter NCT00903526 | University of Modena and Reggio Emilia | — |
| Completed | Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Cand NCT00761267 | Pfizer | Phase 3 |
| Completed | Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk Fo NCT00739934 | Pfizer | Phase 2 |
| Completed | Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins NCT00839540 | Gary E. Stein, Pharm.D. | Phase 4 |
| Terminated | Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins NCT01213823 | Pfizer | — |
| Completed | A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administratio NCT00940017 | Pfizer | Phase 4 |
| Completed | This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed NCT00548262 | Pfizer | Phase 4 |
| Completed | Anidulafungin In Treatment Of Candidemia In Asian Subjects NCT00537329 | Pfizer | Phase 3 |
| Completed | Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug NCT00608335 | Astellas Pharma Inc | Phase 1 |
| Completed | Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the D NCT00607763 | Astellas Pharma Inc | Phase 1 |
| Completed | CRITIC - Treatment of Candidemia and Invasive Candidiasis NCT00670657 | Gilead Sciences | Phase 4 |
| Completed | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections NCT00413218 | Astellas Pharma Inc | Phase 3 |
| Completed | Study of Micafungin in Patients With Invasive Candidiasis or Candidemia NCT00105144 | Astellas Pharma Inc | Phase 3 |
| Completed | Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia NCT00189709 | Astellas Pharma Inc | Phase 3 |
| Completed | Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature In NCT00113191 | Bristol-Myers Squibb | N/A |
| Completed | Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal NCT02088476 | Hacettepe University | — |